Known histone deacetylases (HDACs) are divided into different classes, and HDAC3 belongs to Class I. Through forming multiprotein complexes with the corepressors SMRT and N-CoR, HDAC3 regulates the transcription of a plethora of genes. A growing list of nonhistone substrates extends the role of HDAC3 beyond transcriptional repression. Here, we review data on the composition, regulation and mechanism of action of the SMRT/ N-CoR-HDAC3 complexes and provide several examples of nontranscriptional functions, to illustrate the wide variety of physiological processes affected by this deacetylase. Furthermore, we discuss the implication of HDAC3 in cancer, focusing on leukemia. We conclude with some thoughts about the potential therapeutic efficacies of HDAC3 activity modulation.
Introduction
Initially cloned based on sequence similarity with the previously identified histone deacetylases (HDACs) 1 and 2, HDAC3 was the third mammalian deacetylase to be identified (Yang et al., 1997; Dangond et al., 1998; Emiliani et al., 1998) . Its open reading frame predicted a 428 aa protein, with an estimated molecular mass of 49 kDa. Human HDAC3 is 53% identical with human HDAC1 and 52% identical with human HDAC2 at the amino acid level (Yang et al., 1997; Dangond et al., 1998) . This similarity led to the classification of the above three proteins into one family. HDAC8 would be later added to this class, which includes mammalian enzymes related to yeast Rpd3 (Buggy et al., 2000) . Similar to HDACs 1 and 2, HDAC3 is also ubiquitously expressed. As expected by the sequence identity, early functional analysis of the HDAC3 protein revealed common features with HDACs 1 and 2, namely deacetylation of histone substrates, transcriptional repression when targeted to promoters, as well as physical association with the DNA-binding factor YY1 (Yang et al., 1997; Dangond et al., 1998; Emiliani et al., 1998) . Together, these findings suggested that this ubiquitously expressed protein could be involved in the regulation of mammalian gene expression. On the other hand, HDAC3 contains an intriguingly variable C terminus, with no apparent similarity with other HDACs. This observation led to the hypothesis that HDAC3 may have some unique properties and may not be completely redundant with the other HDACs (Yang et al., 1997) . This is also suggested by the differential localization of HDAC3, which, unlike the predominantly nuclear HDACs 1 and 2, can be found in the nucleus, the cytoplasm and at the plasma membrane (Takami and Nakayama, 2000; Longworth and Laimins, 2006) . Detailed domain analysis has revealed that the protein contains both nuclear import and export signals, which account for this distinct localization pattern (Yang et al., 2002) . The subcellular distribution of HDAC3 agrees with its nuclear function and opens up a whole new world of potential cytoplasmic substrates and regulators.
HDAC3 complexes
Composition A breakthrough in the understanding of the biological role of HDAC3 came with the realization that the enzyme forms a stable complex with nuclear receptor corepressor (N-CoR) and silencing mediator of retinoic and thyroid receptors (SMRT). Biochemical purifications of both N-CoR/SMRT as well as HDAC3-associated proteins, mostly based on immunoaffinity precipitation followed by mass spectrometry, converged to this conclusion Wen et al., 2000; Li et al., 2000; Zhang et al., 2002; Yoon et al., 2003) . At least in HeLa cells, the majority of cellular HDAC3 is found to associate with SMRT and N-CoR complexes. Both N-CoR and SMRT had been discovered as interacting partners of unliganded TR and RAR and mediators of their repressive functions (Chen and Evans, 1995; Horlein et al., 1995) . The two corepressors are high-molecular-weight proteins (B270 kDa), very similar at the amino acid level, containing nuclear receptor-interacting domains as well as multiple repressor domains (Chen and Evans, 1995; Horlein et al., 1995; Ordentlich et al., 1999; Park et al., 1999) .
Although N-CoR and SMRT share many functions, they are likely not completely redundant, as suggested by the lethality of N-CoR deficient mice (Jepsen et al., 2000) . Identification of HDAC3 as the catalytic component of the N-CoR/SMRT complexes provided a mechanistic link between transcriptional repression and histone deacetylation. Via their interactions with a number of different transcription factors, the two corepressors recruit HDAC3 to specific promoters, where the enzyme deacetylates histones and mediates silencing of the corresponding genes.
The purified N-CoR/SMRT complexes contain additional components including transducin b-like 1 (TBL1) Li et al., 2000) , the TBL1-related protein (TBLR1) (Zhang et al., 2002; Yoon et al., 2003) , and G protein pathway suppressor 2 (GPS-2) (Zhang et al., 2002; Yoon et al., 2003) . Both TBL1 and TBLR1 interact directly with SMRT and N-CoR but not with HDAC3 Zhang et al., 2002; Yoon et al., 2003) . In contrast to SMRT and N-CoR, TBL1 and TBLR1 are not required for HDAC3 enzymatic activity Zhang et al., 2002) . Although their functions may be at least partially redundant, TBL1 and TBLR1 are essential for transcriptional repression mediated by TR and other transcription factors Yoon et al., 2003) . Work by Perissi et al. (2004) further indicates that TBL1 and TBLR1 are critical for transcriptional activation by a number of different nuclear receptors examined. According to the proposed model, in addition to their repressive function, TBL1 and TBLR1 also mediate proteasomedependent degradation of SMRT/N-CoR complexes from promoters, to allow for de-repression and subsequent recruitment of coactivators. Thus, the two proteins become essential for gene expression. However, Yoon et al. (2005) failed to observe any effect of TBL1/TBLR1 in transcriptional activation, leaving the exact roles of TBL1/TBLR1 controversial.
Human GPS2 was initially identified via its ability to suppress lethal G protein subunit-activating mutations in the yeast pheromone response pathway (Spain et al., 1996) . Overexpression of GPS2 in mammalian cells has been shown to potently suppress JNK1 activation by serum factors or TNFa (Spain et al., 1996; Jin et al., 1997) and promote the transactivation activities of bovine papillomavirus E2 and tumor suppressor p53 proteins (Breiding et al., 1997; Peng et al., 2001) . Within the N-CoR complex, GPS-2 interacts directly with N-CoR and TBL1 and may aid the assembly and stabilization of the complex (Zhang et al., 2002) . Importantly, the association with N-CoR/HDAC3 is required for GPS-2 to inhibit the JNK pathway (Zhang et al., 2002) . Therefore, these results suggest a role of the N-CoR/HDAC3 complex in the orchestration of gene expression upon various extracellular signals.
Other HDACs (1, 2, 4, 5, 7 and 9) and Sin3 have been reported to interact with N-CoR/SMRT based on different complex purification conditions or interaction assays (Alland et al., 1997; Heinzel et al., 1997; Nagy et al., 1997; Huang et al., 2000; Kao et al., 2000) . Although these interactions could occur in a context-specific fashion, the consensus favors a stable core N-CoR/SMRT complex comprising HDAC3, NCoR/SMRT, TBL1/TBLR1 and GPS-2. It is noteworthy that the core complex of SMRT and N-CoR containing HDAC3, TBL1, TBLR1 and GPS2 is very stable, resistant to high concentration of salt and detergents (Zhang et al., 2002) . Furthermore, the association of HDAC3 with N-CoR/SMRT is evolutionarily conserved, as the yeast SET3 complex is believed to be orthologous to the mammalian N-CoR/SMRT complexes (Pijnappel et al., 2001) .
Substrate specificity
The existence of different HDACs and HDAC complexes raises the question of potential specificity in their enzymatic activities and general functions. Early studies showed that, like HDAC1 and HDAC2, HDAC3 isolated from mammalian cells can deacetylate both H3 and H4 in free histones or nucleosome substrates (Yang et al., 1997; Dangond et al., 1998; Emiliani et al., 1998) . In a more detailed study, Johnson et al. (2002) immunoprecipitated HDAC1, -2, -3 and -6 from cell extracts and compared their kinetics of cleavage of the acetyl group on different lysine residues of hyperacetylated free histones. Although this approach does not provide pure enzymatic preparations, some differences in the preferred lysine residues of the individual complexes were observed. The in vitro results suggested that HDAC3 could completely deacetylate H2A, H4K5Ac and H4K12Ac, but only partially deacetylate H3, H2B, H4K8Ac and H4K16Ac (Johnson et al., 2002) . Compared with HDAC1, HDAC3 deacetylated H4K8Ac, H4K16Ac and H2B at the same rate, but it deacetylated H4K5Ac, H4K12Ac and H2AK5Ac much more rapidly.
Looking at an endogenous retinoic acid-regulated gene, Hartman et al. (2005) observed a similar specificity of the N-CoR/SMRT-HDAC3 complex. Upon ligand removal, recruitment of the corepressor complex re-establishes the repressed state of the gene and this involves progressive deacetylation of lysines in H4 tails. Deacetylation of the H4 lysines occurs in a nonrandom pattern, starting with K5 and followed by K8, K12 and K16, and this ordered process is dependent on the activity of HDAC3 (Hartman et al., 2005) .
Using an in vitro reconstituted chromatin template, Vermeulen et al. (2004) tested histone deacetylation specificity of SMRT/N-CoR complexes. When targeted to preacetylated nucleosomal templates, Sin3/HDAC was found to deacetylate both H3 and H4, whereas the N-CoR/SMRT-HDAC3 complex displayed preferential activity toward H3 (Vermeulen et al., 2004) . This result is somewhat surprising, considering the data discussed above (Johnson et al., 2002; Hartman et al., 2005) . Future work is necessary to reconcile this difference.
A feed-forward mechanism of repression by SMRT/ N-CoR-HDAC3 complexes An emerging theme from several studies on the recruitment of SMRT/N-CoR-HDAC3 complexes to chromatin templates is that histone deacetylation plays a positive feed-forward role in this process. Both SMRT and N-CoR as well as TBL1 and TBLR1 have been shown to bind preferentially hypoacetylated H4 tail (Yoon et al., 2003; Hartman et al., 2005) . Similarly, SMRT/N-CoR-HDAC3 complexes were shown to bind to hypoacetylated chromatin template in vitro, although in this case deacetylated H3 rather than H4 appeared to be important (Vermeulen et al., 2006) . Taken together, these results illustrate a working model (Figure 1 ) in which the enzymatic product of the deacetylase becomes a favorable binding substrate for N-CoR/SMRT complexes, thereby stabilizing and propagating the repressive function of the complex (Hartman et al., 2005; Yoon et al., 2005; Vermeulen et al., 2006) . Further evidence suggests that this feed-forward mechanism could also apply to Sin3/HDAC1/2 mediated repression (Yoon et al., 2005; Vermeulen et al., 2006) .
Regulation of HDAC3 activity
The role of SMRT/N-CoR extends beyond the recruitment of HDAC3 to specific chromatin loci, since their interaction with HDAC3 strongly potentiates HDAC3 enzymatic activity (Wen et al., 2000; Guenther et al., 2001; Zhang et al., 2002) . Guenther et al. (2001) mapped a domain highly conserved between N-CoR and SMRT, required for interaction with HDAC3 and activation of its catalytic function. This deacetylase activating domain (DAD) includes one of the two closely spaced SANT motifs in the N terminus of SMRT and N-CoR. Interestingly, the second SANT motif is part of a histone-interacting domain and functions synergistically with the DAD to promote histone deacetylation (Yu et al., 2003) . The DAD of N-CoR/SMRT binds both the aminoand carboxy-termini of HDAC3 (Guenther et al., 2001) and forms a unique four-helical structure (Codina et al., 2005) . The requirement for an intricately folded HDAC3 surface for interaction with the corepressors might allow for better regulation of its activity and prevent ectopic functions. The necessity for such fine control is also illustrated by the fact that active SMRT-HDAC3 complex formation can occur only after presentation of properly folded HDAC3 to SMRT by chaperones, such as the TCP-1 ring complex, in an ATP-dependent process, termed 'priming' (Guenther et al., 2002) .
More recently, the enzymatic activity of HDAC3 has also been shown to be regulated by phosphorylation/ dephosphorylation. Ser424 of HDAC3 could be phosphorylated by CK2 and dephosphorylated by protein serine/threonine phosphatase 4 (Zhang et al., 2005b) . The latter copurifies with the N-CoR complex and interacts with the N terminus of HDAC3 (Zhang et al., 2005b) . Ser424 phosphorylation on HDAC3 was shown to stimulate its HDAC activity. A similar effect was later proposed for phosphorylation of HDAC3 mediated by the DNA-dependent protein kinase (DNA-PK, Jeyakumar et al., 2007) . Interestingly, HDAC3 also Role of HDAC3 in cancer therapy P Karagianni and J Wong localizes to the cellular membrane and is a substrate for Src, a membrane associated tyrosine kinase, suggesting a potential role of HDAC3 in cytoplasmic signal transduction (Longworth and Laimins, 2006) . Furthermore, HDAC3 activity can also be regulated indirectly through phosphorylation of its associated proteins. For instance, IKKa-mediated phosphorylation of RelA/p65 and SMRT on nuclear factor-kB (NF-kB)-regulated promoters results in disruption of the complex and subsequent de-repression of the corresponding genes (Hoberg et al., 2006) . In addition to protein-protein interactions and phosphorylation, subcellular localization may serve as another regulatory mechanism for HDAC3. For example, export of the N-CoR complex to the cytoplasm in response to interleukin (IL)-1b stimulation has been proposed as a mechanism of de-repression of a set of NF-kB regulated genes (Baek et al., 2002) . This regulation is mediated by TAB2, a known activator of the NF-kB pathway (Takaesu et al., 2000; Baek et al., 2002) . The reverse process, nuclear translocation of HDAC3, has been described as a mechanism of inhibition of PPARg by TNFa (Gao et al., 2006) . Cytoplasmic HDAC3 was shown to associate with IkBaand TNFa-treatment induced degradation of the latter and HDAC3 release, allowing it to enter the nucleus and repress the activity of PPARg (Gao et al., 2006) .
Recently, subcellular localization of HDAC3 was also shown to be controlled by caspase-dependent cleavage during apoptosis (Escaffit et al., 2007) . Removal of the C-terminal part of HDAC3, which is required for nuclear localization, results in accumulation of the cleaved protein to the cytoplasm. The redistribution of HDAC3 is required for proapoptotic gene activation and subsequent death of several human cell types (Escaffit et al., 2007) . Interestingly, the cleaved HDAC3 protein appears to maintain its deacetylase enzymatic activity, raising a possible cytoplasmic role for the cleaved HDAC3 (Escaffit et al., 2007) .
However, the question of whether cytoplasmic HDAC3 is enzymatically active still remains open. Theoretically, evolution may have favored a model in which the enzyme is inactive in the cytoplasm. This would prevent aberrant functions of this key regulatory protein in the cytoplasm. However, HDAC3 might also have cytoplasmic functions. As discussed next, several nonhistone proteins including cytoplasmic proteins have been shown to be deacetylated by this enzyme. Given that proper association with N-CoR/SMRT is required for the enzyme to be functional toward histones (Wen et al., 2000; Guenther et al., 2001; Zhang et al., 2002) , an intriguing question is whether a similar mechanism might also be required for an active cytoplasmic HDAC3 and/or toward nonhistone substrates.
Diverse biological functions of HDAC3
Repression of transcription through histone deacetylation HDAC3 and the N-CoR/SMRT complex regulate a wide repertoire of cellular processes, including differentiation, proliferation and apoptosis (Jepsen and Rosenfeld, 2002) . At an organismal level, they play critical role in development, metabolism and inflammation. Their physiological function is thought to be largely mediated through their ability to facilitate transcriptional repression by a number of different transcription factors. Histone deacetylation is thought to repress gene expression by at least two different mechanisms. First, removal of the acetyl group increases the local positive charge of histones, increasing their affinity for the negatively charged DNA. This generates a tight chromatin structure, refractory to transcription. Moreover, deacetylation reduces the affinity of bromodomain-containing coactivators (Zeng and Zhou, 2002) . In this general way, the N-CoR/SMRT complex mediates repression of unliganded nuclear receptors, such as TR, RAR, RXR, PPAR and orphan nuclear receptors, such as Rev-Erb, COUP-TFs, and DAX1 (Shibata et al., 1997; Zamir et al., 1997; Crawford et al., 1998; Jepsen and Rosenfeld, 2002; Yin and Lazar, 2005) . Generally, an unliganded receptor associates with N-CoR/SMRT, but this interaction is lost as a result of the receptor conformational change upon ligand binding. Sometimes, repression occurs independently of the presence or absence of ligand. For instance, cyclin D1 can repress both basal as well as ligand-dependent functions of TR and PPARg, by recruiting HDAC3 Fu et al., 2005) . In other examples, it is the antagonist-bound receptor that interacts with N-CoR/ SMRT to repress transcription (Jackson et al., 1997; Smith et al., 1997; Lavinsky et al., 1998) . In addition to nuclear receptors, other transcription factors, including Mad, BCL6, Pit1 and ETO also use corepressor complexes to establish and maintain the inactive state of their target genes (Heinzel et al., 1997; Huynh and Bardwell, 1998; Lutterbach et al., 1998; Wang et al., 1998; Xu et al., 1998) .
Although in some cases repression is a result of coordinated function of multiple HDAC complexes, in others, HDAC3 is the preferred enzyme for this task. For instance, HDAC3 is critically important for TRmediated repression Yoon et al., 2005) . Li et al. (2002) have shown that unliganded TR recruits only N-CoR and SMRT/HDAC3 complexes for repression, whereas another transcription factor, Mad1, recruits only the Sin3/HDAC1/2 deacetylase complex. Interestingly, in addition to their effect on covalent histone modifications, N-CoR and HDAC3 are also required for recruitment of the SNF2H chromatin remodeller to facilitate unliganded TR-mediated repression (Alenghat et al., 2006) .
But even in cases where multiple complexes are required for repression, their roles do not seem to be redundant, as suggested by work on tamoxifen-bound ER (Liu and Bagchi, 2004) . Examining the recruitment of different factors on endogenous promoters, it was observed that both N-CoR/HDAC3 and the NuRD complex were recruited by tamoxifen-complexed ER, but in a sequential manner, following a strict choreography of events (Liu and Bagchi, 2004 ). The distinct functions of different HDACs and HDAC complexes are also suggested by overexpression/downregulation studies as well as developmental profiling of individual HDACs in Drosophila (Cho et al., 2005; Foglietti et al., 2006) . Such studies reveal unique sets of genes regulated by each enzyme. Surprisingly, similar numbers of genes were found to be repressed and activated in each case, perhaps through both direct and indirect effects (Cho et al., 2005; Foglietti et al., 2006) .
Deacetylation of nonhistone substrates
Acetylation regulates the localization, stability, interactions and activity of a growing number of nonhistone proteins (Kouzarides, 2000; Glozak et al., 2005) . Examples include transcription factors, signaling molecules, molecular chaperones and enzymes (Figure 2) . By reversing this modification, HDAC3 obtains a critical role in various processes. For instance, the NF-kB protein RelA was shown to undergo inducible acetylation, which renders it a poor-binding substrate for IkB (Chen et al., 2001) . HDAC3 regulates the duration of NF-kB action by deacetylating RelA and promoting its interaction with inhibitory-kB (IkB), thus leading to its nuclear export, termination of NF-kB signaling, as well as replenishment of the cytoplasmic pool of RelA-IkB (Chen et al., 2001) . HDAC3 also deacetylates SRY, a master regulator of testis organogenesis, regulating its subcellular localization and activity (Thevenet et al., 2004) . In addition, HDAC3-mediated deacetylation of p53 upon shear stress appears to be critical for differentiation of stem cells into epithelial cells (Zeng et al., 2006) . Furthermore, HDAC3 deacetylates myocyte enhancer factor 2, a transcription factor important for differentiation, apoptosis and survival of different cell types (Gregoire et al., 2007) , as well as glial cell missing (GCMa), which is important in development and differentiation (Chuang et al., 2006) . Interestingly, in both cases, HDAC3 was also found to deacetylate the responsible acetyltransferases (PCAF and p300/CBP) for these proteins (Chuang et al., 2006; Gregoire et al., 2007) . Moreover, a subset of N-CoR-HDAC3 complex copurifies with CBP in HeLa cells and N-CoR can interact directly with CBP (Cowger and Torchia, 2006) . Deacetylation of the acetyltransferases was shown to inhibit their function in the above examples. Finally, HDAC3 negatively regulates the activity of transcriptional elongation factor P-TEFb through deacetylation of CDK9 subunit (Fu et al., 2007) . We expect that more and more proteins will be identified to be regulated through deacetylation by HDAC3 or its associated protein complexes.
HDAC3 and the histone code: beyond deacetylation
The histone deacetylase activity of the N-CoR/SMRT complex ranks it among the key factors in chromatin regulation. However, in addition to the direct effect on histone acetylation, the HDAC3-N-CoR complex may impact chromatin structure in other ways. For instance, a recent study showed that HDAC3 is recruited to the mitotic chromosomes through its interaction with A-kinase anchor protein 95 (AKAP95) and another related protein, homologous to AKAP95 (HA95) (Li et al., 2006) . HDAC3-mediated deacetylation of histones during mitosis is required for subsequent phosphorylation of H3 on Ser10 by the aurora kinase B (Li et al., 2006) . H3 Ser10 phosphorylation is, in turn, required for HP1 dissociation, proper chromosome condensation and segregation (Wei et al., 1999; Fischle et al., 2005; Hirota et al., 2005) . This example illustrates a nontranscriptional effect of HDAC3 during mitosis.
An interesting twist to the story of N-CoR/HDAC3-mediated repression came with the identification of Figure 2 Representative nonhistone substrates of histone deacetylase-3 (HDAC3). In addition to histones, an increasing number of proteins has been shown to be substrates for HDAC3. Deacetylation of these proteins by HDAC3 affects various aspects, ranging from subcellular localization, DNA binding to protein stability.
Role of HDAC3 in cancer therapy P Karagianni and J Wong JMJD2A as an associated protein with the complex (Zhang et al., 2005a) . JMJD2A has histone demethylase activity for H3 K9 and K36 (Klose et al., 2006; Whetstine et al., 2006) . Its double tudor domain binds methylated H3 K4 and H4 K20 (Huang et al., 2006) . Although only small fraction of JMJD2A is in complex with N-CoR (Zhang et al., 2005a) , the physical association of this demethylase with the deacetylase complex may imply functional interplay between the two activities and potential cross-talk between the modifications they catalyse.
HDAC3 and cancer
Initial implication of HDAC3 in carcinogenesis was based on correlative studies reporting aberrant expression and/or localization of HDAC3 in various tumors. For instance, increased HDAC3 mRNA and protein was observed in squamous cell lung carcinomas (Bartling et al., 2005) as well as in astrocytic glial tumors (Liby et al., 2006) . The latter also display deregulated, strongly pronounced cytoplasmic HDAC3 protein localization and increased number of mRNA and protein isoforms compared to nonmalignant tissues (Liby et al., 2006) . Silencing of HDAC3 in colon cancer cell lines, which normally express high levels of the protein, resulted in cell growth inhibition, differentiation and increased apoptosis (Wilson et al., 2006) . These effects were thought to be mediated by regulation of p21 gene (Wilson et al., 2006) . At a mechanistic level, HDAC3 was shown to be recruited by the tumor antigen MAGE-A to impair the transactivation of the tumor suppressor p53, thereby conferring chemoresistance (Monte et al., 2006) . Finally, Narita et al. (2005) , based on studies with human maxillary carcinoma cells, proposed that inhibition of HDAC3 combined with hyperthermia may provide an efficient therapeutic approach for cancer.
HDAC3 in leukemia
Leukemia is distinguished into different types, depending on what blood cell line is affected. The disease can also be acute or chronic. Acute leukemia accounts for about one-third of all childhood cancers and is categorized to acute lymphoblastic (ALL) and acute myeloid (AML). A recurrent theme in this disease is a reciprocal and balanced chromosomal rearrangement that generates an oncogenic fusion protein. The oncogenic properties of the fusion protein are usually a result of combination of the DNA-binding domain of one transcription factor with the transcriptional coregulator-interacting domain of another factor. Many of these fusion proteins have been shown to interact with N-CoR/SMRT corepressors and compelling evidence shows that aberrant recruitment of the correpressor proteins correlates with the oncogenic activities of the fusion proteins. For instance, N-CoR/SMRT-HDAC3 and other corepressors are aberrantly recruited to the promoters of AML1 (renamed RUNX1) target genes via their interaction with the TEL moiety of TEL-AML1 (Chakrabarti and Nucifora, 1999; Fenrick et al., 1999; Guidez et al., 2000) . The latter is the fusion protein generated in about one fourth of pediatric B-cell ALL patients, as a result of the t(12;21) translocation (Romana et al., 1995; Shurtleff et al., 1995) . Normally, AML1 positively regulates a number of genes required for hematopoiesis (Okuda et al., 1996; Wang et al., 1996; Tanaka et al., 1997) , whereas repression of these genes by TEL-AML1 and its interacting corepressors is thought to contribute to the leukemic phenotype (Frank et al., 1995; Fears et al., 1997; Uchida et al., 1997; Guidez et al., 2000) . Similarly, a common translocation in AML patients, t(8;21) results in the generation of fusion protein AML1 and ETO (eight-twenty-one or MTG8), which also recruits corepressors and HDACs by the C terminus of ETO, leading to repression of the AML1 target genes (Rowley, 1982; Erickson et al., 1992; Gelmetti et al., 1998; Lutterbach et al., 1998; Wang et al., 1998; Amann et al., 2001) . Analogous effect has been described for the fusion protein MTG16a-AML1, resulting from the t(16;21) translocation, present in a number of AML patients (Gamou et al., 1998; Hoogeveen et al., 2002) .
Acute promyelocytic leukemia (APL) is a subtype of AML characterized by excess promyelocytes and deficiency in cells of the myeloid lineage. APL is commonly due to translocations affecting the RARa locus (reviewed by Zelent et al., 2001) . The most common genetic cause of APL is t(15;17), which rearranges the PML and RAR genes. As a consequence, a fusion protein between PML and the RARa receptor is produced and occupies RARE-containing promoters. Normal regulation of these promoters depends on RARa-mediated repression in the absence of retinoic acid and activation in the presence of ligand. This process is critical for proper differentiation of myeloid cell lineages. Contrary to full-length RAR, PML-RARa does not respond to physiological RA levels. Therefore, the fusion protein functions as a constitutive repressor of the RAR-target genes, blocking differentiation and resulting in leukemogenesis. However, this disease responds well to pharmacological levels of all-transretinoic-acid (ATRA) and patients usually achieve complete remission after treatment (Huang et al., 1988) . This treatment restores normal granulocyte differentiation and provides a paradigm of differentiation cancer therapy. Atsumi et al. (2006) showed that the N-CoR/HDAC3 complex is involved in this constitutive repression in PML-RARa-expressing cells and that RNA interference against HDAC3 could activate expression of the above genes. In addition to promoting histone deacetylation, HDAC3 has been proposed to aid silencing of the PML-RARa targeted genes by recruiting MBD1 (Villa et al., 2006) .
A different APL-causing translocation, t(11;17), gives the PLZF-RARa fusion protein, which functions similarly to the PML-RARa protein discussed above, maintaining repression of critical genes for blood cell differentiation (Dong et al., 1996) . However, in contrast to PML-RARa, PLZF-RARa is insensitive to ATRA (Licht et al., 1995) . This is because PLZF-RAR maintains association with corepressors N-CoR/SMRT and HDACs, through the PLZF moiety, in an RAresistant fashion (Hong et al., 1997; Grignani et al., 1998; Lin et al., 1998) . As expected, HDAC activity plays a critical role in the pathogenesis of these leukemias and a combination of retinoic acid with HDAC inhibitors has been proposed as a potential therapeutic strategy (Grignani et al., 1998; Lin et al., 1998) .
In support of a critical role of SMRT/N-CoR-HDAC3 in leukemias, Racanicchi et al. (2005) achieved restoration of differentiation in AML1/ETO and PML/ RAR-expressing cells by overexpressing specific N-CoR fragments. By interacting with the fusion proteins, not only did the overexpressed fragments block their interaction with N-CoR/SMRT, but they also disrupted the complex and targeted the fusion protein for degradation (Racanicchi et al., 2005) . These findings highlight the importance of understanding the molecular basis of the malignancy to design novel therapeutic strategies. They also suggest that simultaneous targeting of multiple pathogenic players may provide a more efficient means of fighting the disease.
HDAC3 as an attractive therapeutic target
In the 30-year period following the discovery of chemical inhibitors of HDACs (Riggs et al., 1977; Vidali et al., 1978) , such pharmacological compounds have transited from the laboratory bench to the treatment of cancer patients (reviewed by Johnstone, 2002; Karagiannis and El-Osta, 2007) . Although early trials have used broad-spectrum inhibitors, selective targeting of specific deacetylases may provide a better alternative.
Pharmacological treatment of cancer commonly aims to one or more of the following effects: (1) cell cycle arrest, (2) differentiation and (3) apoptosis of the malignant cells. Evidence illustrates key roles of HDAC3 in all three processes. Differential display cloning of HDAC3 from stimulated T cells alluded to a possible role of this enzyme in cell cycle progression, further supported by the fact that both overexpression and downregulation of this molecule causes G2/M arrest (Dangond et al., 1998; Wilson et al., 2006) . Compared to other HDACs, HDAC3 and HDAC1 downregulation had more pronounced effect on cancer cell proliferation (Glaser et al., 2003) . Critical roles of HDAC3 in cellular differentiation have also been described in different contexts. For instance, HDAC3 enzymatic function is utilized by Jun dimerization protein 2 (JDP2) to maintain the c-jun in its inactive state (Jin et al., 2002) . Similarly, HDAC3 is utilized by PPARg to maintain transcriptional repression of its target genes and block adipogenesis (Fajas et al., 2002) as well as by Runx2, to mediate repression of osteoblast genes (Schroeder et al., 2004) . In contrast, the tumor suppressor Kruppel-like factor-6 (KLF6) recruits HDAC3 to mediate repression of the proto-oncogene d-like 1 (Dlk1), which encodes an inhibitor of adipocyte differentiation, thus promoting adipogenesis . HDAC3 also represses the transcription of the gene encoding the growth-differentiation factor 11 (Gdf11), which controls several developmental processes (Zhang et al., 2004) . Finally, two recent publications illustrate a more specific implication of HDAC3 in apoptosis. The first study shows that cytoplasmic relocalization of cleaved HDAC3 to be critical for cell death (Escaffit et al., 2007) , whereas the other demonstrates a transcriptional effect of HDAC3 on c-jun (Xia et al., 2007) .
The above findings indicate that HDAC3 could be a suitable target for cancer therapy. Particularly in the case of leukemia, research generates hope for targeting HDAC3 in the design of novel therapeutic strategies. Understanding the context of HDAC3 function in different diseases could benefit combinatorial pharmacological approaches as well as individualized strategies based on the unique profile of each patient.
